La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Intellia Therapeutics Bilan de santé
Santé financière contrôle des critères 6/6
Intellia Therapeutics possède un total de capitaux propres de $971.1M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $1.2B et de $220.5M.
Informations clés
0%
Ratio d'endettement
US$0
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$691.07m |
| Fonds propres | US$971.06m |
| Total du passif | US$220.47m |
| Total des actifs | US$1.19b |
Mises à jour récentes de la santé financière
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07
Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Recent updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Analyse de la situation financière
Passif à court terme: Les actifs à court terme de NTLA ( $757.2M ) dépassent ses passifs à court terme ( $105.1M ).
Passif à long terme: Les actifs à court terme de NTLA ( $757.2M ) dépassent ses passifs à long terme ( $115.4M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: NTLA est sans dette.
Réduire la dette: NTLA n'a eu aucune dette au cours des 5 dernières années.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: NTLA dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: NTLA dispose d'une marge de trésorerie suffisante pour 1.6 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 34 % chaque année.